We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Erythrocyte membrane-cloaked polymeric nanoparticles for controlled drug loading and release

    Santosh Aryal

    Department of NanoEngineering, University of California, San Diego, 9500 Gilman Drive, MC-0448, La Jolla, CA 92093-0448, USA

    Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA

    Search for more papers by this author

    ,
    Che-Ming J Hu

    Department of NanoEngineering, University of California, San Diego, 9500 Gilman Drive, MC-0448, La Jolla, CA 92093-0448, USA

    Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA

    Search for more papers by this author

    ,
    Ronnie H Fang

    Department of NanoEngineering, University of California, San Diego, 9500 Gilman Drive, MC-0448, La Jolla, CA 92093-0448, USA

    Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA

    Search for more papers by this author

    ,
    Diana Dehaini

    Department of NanoEngineering, University of California, San Diego, 9500 Gilman Drive, MC-0448, La Jolla, CA 92093-0448, USA

    Search for more papers by this author

    ,
    Cody Carpenter

    Department of NanoEngineering, University of California, San Diego, 9500 Gilman Drive, MC-0448, La Jolla, CA 92093-0448, USA

    Search for more papers by this author

    ,
    Dong-Er Zhang

    Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA

    Search for more papers by this author

    &
    Liangfang Zhang

    * Author for correspondence

    Department of NanoEngineering, University of California, San Diego, 9500 Gilman Drive, MC-0448, La Jolla, CA 92093-0448, USA. .

    Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA

    Search for more papers by this author

    Email the corresponding author at zhang@ucsd.edu

    Published Online:5 Aug 2013https://doi.org/10.2217/nnm.12.153

    Abstract

    Aim: Polymeric nanoparticles (NPs) cloaked by red blood cell membrane (RBCm) confer the combined advantage of both long circulation lifetime and controlled drug release. The authors carried out studies to gain a better understanding of the drug loading, drug-release kinetics and cell-based efficacy of RBCm-cloaked NPs. Materials & methods: Two strategies for loading doxorubicin into the RBCm-cloaked NPs were compared: physical encapsulation and chemical conjugation. In vitro efficacy was examined using the acute myeloid leukemia cell line, Kasumi-1. Results: It was found that the chemical conjugation strategy resulted in a more sustained drug release profile, and that the RBCm cloak provided a barrier, retarding the outward diffusion of encapsulated drug molecules. It was also demonstrated that RBCm-cloaked NPs exhibit higher toxicity in comparison with free doxorubicin. Conclusion: These results indicate that the RBCm-cloaked NPs hold great promise to become a valuable drug-delivery platform for the treatment of various diseases such as blood cancers.

    Original submitted 27 February 2012; Revised submitted 27 August 2012; Published online 14 February 2013

    Papers of special note have been highlighted as: ▪ of interest

    References

    • 1  Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7(9),771–782 (2008).▪ Excellent review of recent advances in nanoparticle therapeutics.
      Google Scholar
    • 2  Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov.9(8),615–627 (2010).▪ Excellent review of recent advances in nanoparticle therapeutics.
      Medline CASGoogle Scholar
    • 3  Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2(12),751–760 (2007).
      Medline CASGoogle Scholar
    • 4  Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano3(1),16–20 (2009).▪ Excellent review on both challenges and opportunities in the emerging field of nanoparticle therapeutics.
      Medline CASGoogle Scholar
    • 5  Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm.5(4),505–515 (2008).
      Medline CASGoogle Scholar
    • 6  Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl.49(36),6288–6308 (2010).
      Medline CASGoogle Scholar
    • 7  Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol.2(4),249–255 (2007).
      Medline CASGoogle Scholar
    • 8  Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Design16(21),2298–2307 (2010).
      Medline CASGoogle Scholar
    • 9  Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA108(27),10980–10985 (2011).▪ First report of the preparation and characterization of red blood cell membrane-cloaked nanoparticles as a new biomimetic drug delivery system.
      Medline CASGoogle Scholar
    • 10  Dodge JT, Mitchell C, Hanahan DJ. The preparation and chemical characteristics of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem. Biophys.100,119–130 (1963).
      Medline CASGoogle Scholar
    • 11  Aryal S, Hu CM, Zhang L. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol. Pharm.8(4),1401–1407 (2011).
      Medline CASGoogle Scholar
    • 12  Tong R, Cheng J. Ring-opening polymerization-mediated controlled formulation of polylactide–drug nanoparticles. J. Am. Chem. Soc.131(13),4744–4754 (2009).▪ Excellent report of an elegant control over regioselectivity during the initiation step of synthesizing polymer–drug conjugates.
      Medline CASGoogle Scholar
    • 13  Aryal S, Hu CM, Zhang L. Polymer–cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano4(1),251–258 (2010).
      Medline CASGoogle Scholar
    • 14  Popielarski SR, Pun SH, Davis ME. A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization. Bioconjug. Chem.16(5),1063–1070 (2005).
      Medline CASGoogle Scholar
    • 15  Fang RH, Aryal S, Hu CM, Zhang L. Quick synthesis of lipid–polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir26(22),16958–16962 (2010).
      Medline CASGoogle Scholar
    • 16  Tong R, Cheng J. Controlled synthesis of camptothecin–polylactide conjugates and nanoconjugates. Bioconjug. Chem.21(1),111–121 (2010).
      Medline CASGoogle Scholar
    • 17  Gao W, Chan JM, Farokhzad OC. pH-responsive nanoparticles for drug delivery. Mol. Pharm.7(6),1913–1920 (2010).
      Medline CASGoogle Scholar
    • 18  Gu F, Zhang L, Teply BA et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA105(7),2586–2591 (2008).
      Medline CASGoogle Scholar
    • 19  Takae S, Miyata K, Oba M et al. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J. Am. Chem. Soc.130(18),6001–6009 (2008).
      Medline CASGoogle Scholar
    • 20  Zhang L, Chan JM, Gu FX et al. Self-assembled lipid–polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano2(8),1696–1702 (2008).
      Medline CASGoogle Scholar
    • 21  Pornpattananangkul D, Zhang L, Olson S et al. Bacterial toxin-triggered drug release from gold nanoparticle-stabilized liposomes for the treatment of bacterial infection. J. Am. Chem. Soc.133(11),4132–4139 (2011).
      Medline CASGoogle Scholar
    • 22  Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Control. Release79(1–3),123–135 (2002).
      Medline CASGoogle Scholar
    • 23  Li J, Jiang G, Ding F. The effect of pH on the polymer degradation and drug release from PLGA–mPEG microparticles. J. Appl. Polym. Sci.109(1),475–482 (2008).
      CASGoogle Scholar
    • 24  Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J. Pharm. Sci.50,874–875 (1961).
      Medline CASGoogle Scholar
    • 25  Siepmann J, Peppas NA. Higuchi equation: derivation, applications, use and misuse. Int. J. Pharm.418(1),6–12 (2011).
      Medline CASGoogle Scholar
    • 26  Budhian A, Siegel SJ, Winey KI. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int. J. Pharm.346(1–2),151–159 (2008).
      Medline CASGoogle Scholar
    • 27  Pitt CG, Schindler A. The kinetics of drug cleavage and release from matrices containing covalent polymer–drug conjugates. J. Control. Release33(3),391–395 (1995).
      CASGoogle Scholar
    • 28  Lowenberg B, Ossenkoppele GJ, van Putten W et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N. Engl. J. Med.361(13),1235–1248 (2009).
      MedlineGoogle Scholar
    • 29  Hu C-MJ, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab.10(8),836–841 (2009).
      Medline CASGoogle Scholar
    • 30  Ayen WY, Garkhal K, Kumar N. Doxorubicin-loaded (PEG)3–PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. Mol. Pharm.8(2),466–478 (2011).
      Medline CASGoogle Scholar
    • 31  Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano–aggregates stabilized by doxorubicin–PEG–folate conjugate. J. Control. Release100(2),247–256 (2004).
      Medline CASGoogle Scholar
    • 32  Huwyler J, Cerletti A, Fricker G, Eberle AN, Drewe J. By-passing of P-glycoprotein using immunoliposomes. J. Drug Target.10(1),73–79 (2002).
      Medline CASGoogle Scholar
    • 33  Rapoport N, Marin A, Luo Y, Prestwich GD, Muniruzzaman M. Intracellular uptake and trafficking of pluronic micelles in drug-sensitive and MDR cells: effect on the intracellular drug localization. J. Pharm. Sci.91(1),157–170 (2002).
      Medline CASGoogle Scholar
    • 34  Sahoo SK, Labhasetwar V. Enhanced anti proliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharm.2(5),373–383 (2005).
      Medline CASGoogle Scholar
    • 35  Dordal MS, Jackson-Stone M, Ho AC, Winter JN, Atkinson AJ. Decreased intracellular compartmentalization of doxorubicin in cell lines expressing P-glycoprotein. J. Pharmacol. Exp. Ther.271(3),1286–1290 (1994).
      Medline CASGoogle Scholar
    • 36  Mizutani M, Yamaguchi M, Miwa H et al. Frequent expression of MDR1 and MDR3 genes in acute myelocytic leukemia cells with t(8;21) (q22;q22). Int. J. Oncol.10(3),473–479 (1997).
      Medline CASGoogle Scholar
    • 37  Rao J, Xu Dr, Zheng Fm et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J. Transl. Med.9,71 (2011).
      Medline CASGoogle Scholar